Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 2Carcinoma, Medullary 2Zollinger-Ellison Syndrome 1Vipoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Paraganglioma 1Neuroendocrine Tumors 1Neoplastic Syndromes, Hereditary 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia 1Kidney Neoplasms 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Glioblastoma 1Congenital Abnormalities 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Brain Neoplasms 1Birt-Hogg-Dube Syndrome 1Advanced Malignant Solid Neoplasm 1

Interventions

Trastuzumab 2tipifarnib 1Sorafenib 1Salts 1Oxaliplatin 1Octreotide 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Gefitinib 1Floxuridine 1Everolimus 1Disulfides 1Bevacizumab 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Vipoma × Everolimus × Clear all
NCT01229943 2022-08-04

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
150 enrolled 12 charts

Vipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡